Interní Med. 2011; 13(10): 378-382

Pharmacotherapy after myocardial infarction

prof.MUDr.Jindřich Špinar, CSc.¹, prof.MUDr.Jiří Vítovec, CSc.², prof.MUDr.Lenka Špinarová, CSc.²

¹ Interní kardiologická klinika, FN Brno a LF MU

² Interní kardioangiologická klinika, FN u sv. Anny a LF MU, Brno

Early reperfusion is currently the mainstay of treatment for acute coronary syndrome. Thanks to a network of 22 catheterization centres, the

Czech Republic is among countries with a high availability of reperfusion therapy. Approximately 28,000 patients are thus treated annually.

Successful reperfusion must be followed by lifestyle measures including not smoking, maintaining a healthy weight, etc. All this must be

complemented with effective pharmacotherapy whose goal is to prevent left ventricular remodelling, coronary artery restenosis, rethrombosis

and arrhythmias. Four drug groups are designed for this purpose: renin-angiotensin-aldosterone system blockers, beta blockers,

antiplatelet agents and statins. The FARIM (FARmakoterapie po Infarktu Myokardu – Pharmacotherapy after Myocardial Infarction) survey

conducted in the practices of physicians in the Czech Republic found a very good rate of prescribing the recommended drugs with each

of the drug groups mentioned above being prescribed in about 90% of patients after myocardial infarction. Achieving the target levels of

blood pressure and cholesterol was also found to be of a good standard while the doses of some agents were inadequate.

Keywords: myocardial infarction, pharmacotherapy, doses, target levels

Published: October 1, 2011  Show citation